Skip to main content
Figure 4 | BMC Immunology

Figure 4

From: CTLA4-Ig (abatacept) therapy modulates T cell effector functions in autoantibody-positive rheumatoid arthritis patients

Figure 4

Treg frequency is diminished. PBMCs from baseline and 3 months following treatment (n=12) were obtained and multicolor flow cytometry was performed. A general reduction in frequency of several Treg associated markers could be seen (A-G). (A) The graph depicts a representative staining of CD4+FOXP3+ Treg before and after treatment. (B) The graph displays CD4+FOXP3+ Treg, (C) Helios+ T cells, (D) CD4+CD39+ T cells, (E) CD45RA+FOXP3+ Treg, (F) CTLA4+ FOXP3+Treg, and (G) CD39+FOXP3+ Treg.

Back to article page